Literature DB >> 27161624

Silver and Nitrate Oppositely Modulate Antimony Susceptibility through Aquaglyceroporin 1 in Leishmania (Viannia) Species.

Juvana M Andrade1, Elio H Baba1, Ricardo A Machado-de-Avila2, Carlos Chavez-Olortegui3, Cynthia P Demicheli4, Frédéric Frézard3, Rubens L Monte-Neto5, Silvane M F Murta5.   

Abstract

Antimony (Sb) resistance in leishmaniasis chemotherapy has become one of the major challenges to the control of this spreading worldwide public health problem. Since the plasma membrane pore-forming protein aquaglyceroporin 1 (AQP1) is the major route of Sb uptake in Leishmania, functional studies are relevant to characterize drug transport pathways in the parasite. We generated AQP1-overexpressing Leishmania guyanensis and L. braziliensis mutants and investigated their susceptibility to the trivalent form of Sb (Sb(III)) in the presence of silver and nitrate salts. Both AQP1-overexpressing lines presented 3- to 4-fold increased AQP1 expression levels compared with those of their untransfected counterparts, leading to an increased Sb(III) susceptibility of about 2-fold. Competition assays using silver nitrate, silver sulfadiazine, or silver acetate prior to Sb(III) exposure increased parasite growth, especially in AQP1-overexpressing mutants. Surprisingly, Sb(III)-sodium nitrate or Sb(III)-potassium nitrate combinations showed significantly enhanced antileishmanial activities compared to those of Sb(III) alone, especially against AQP1-overexpressing mutants, suggesting a putative nitrate-dependent modulation of AQP1 activity. The intracellular level of antimony quantified by graphite furnace atomic absorption spectrometry showed that the concomitant exposure to Sb(III) and nitrate favors antimony accumulation in the parasite, increasing the toxicity of the drug and culminating with parasite death. This is the first report showing evidence of AQP1-mediated Sb(III) susceptibility modulation by silver in Leishmania and suggests the potential antileishmanial activity of the combination of nitrate salts and Sb(III).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27161624      PMCID: PMC4958230          DOI: 10.1128/AAC.00768-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Blasticidin resistance: a new independent marker for stable transfection of Leishmania.

Authors:  S Goyard; S M Beverley
Journal:  Mol Biochem Parasitol       Date:  2000-05       Impact factor: 1.759

Review 2.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Telomeric gene deletion and intrachromosomal amplification in antimony-resistant Leishmania.

Authors:  Angana Mukherjee; Sébastien Boisvert; Rubens Lima do Monte-Neto; Adriano C Coelho; Frederic Raymond; Rita Mukhopadhyay; Jacques Corbeil; Marc Ouellette
Journal:  Mol Microbiol       Date:  2013-03-06       Impact factor: 3.501

4.  Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.

Authors:  Jorge Arevalo; Luis Ramirez; Vanessa Adaui; Mirko Zimic; Gianfranco Tulliano; César Miranda-Verástegui; Marcela Lazo; Raúl Loayza-Muro; Simonne De Doncker; Anne Maurer; Francois Chappuis; Jean-Claude Dujardin; Alejandro Llanos-Cuentas
Journal:  J Infect Dis       Date:  2007-05-03       Impact factor: 5.226

Review 5.  Aquaglyceroporins and metalloid transport: implications in human diseases.

Authors:  Hiranmoy Bhattacharjee; Barry P Rosen; Rita Mukhopadhyay
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin.

Authors:  Benjamin Gourbal; Niluefer Sonuc; Hiranmoy Bhattacharjee; Danielle Legare; Shyam Sundar; Marc Ouellette; Barry P Rosen; Rita Mukhopadhyay
Journal:  J Biol Chem       Date:  2004-05-11       Impact factor: 5.157

7.  Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania.

Authors:  Kelly A Robinson; Stephen M Beverley
Journal:  Mol Biochem Parasitol       Date:  2003-05       Impact factor: 1.759

8.  Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon.

Authors:  Jorge Augusto de Oliveira Guerra; Suzane Ribeiro Prestes; Henrique Silveira; Leila Inês de Aguiar Raposo Câmara Coelho; Pricila Gama; Aristoteles Moura; Valdir Amato; Maria das Graças Vale Barbosa; Luiz Carlos de Lima Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2011-03-08

9.  Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.

Authors:  Goutam Mandal; Srotoswati Mandal; Mansi Sharma; Karen Santos Charret; Barbara Papadopoulou; Hiranmoy Bhattacharjee; Rita Mukhopadhyay
Journal:  PLoS Negl Trop Dis       Date:  2015-02-25

10.  Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs.

Authors:  Jane C Munday; Anthonius A Eze; Nicola Baker; Lucy Glover; Caroline Clucas; David Aguinaga Andrés; Manal J Natto; Ibrahim A Teka; Jennifer McDonald; Rebecca S Lee; Fabrice E Graf; Philipp Ludin; Richard J S Burchmore; C Michael R Turner; Andy Tait; Annette MacLeod; Pascal Mäser; Michael P Barrett; David Horn; Harry P De Koning
Journal:  J Antimicrob Chemother       Date:  2013-11-13       Impact factor: 5.790

View more
  6 in total

1.  Synthesis and evaluation of the antileishmanial activity of silver compounds containing imidazolidine-2-thione.

Authors:  Patrícia Ferreira Espuri; Larissa Luiza Dos Reis; Eduardo de Figueiredo Peloso; Vanessa Silva Gontijo; Fábio Antônio Colombo; Juliana Barbosa Nunes; Carine Ervolino de Oliveira; Eduardo T De Almeida; Débora E S Silva; Jessica Bortoletto; Daniel Fonseca Segura; Adelino V G Netto; Marcos José Marques
Journal:  J Biol Inorg Chem       Date:  2019-04-04       Impact factor: 3.358

2.  Global genome diversity of the Leishmania donovani complex.

Authors:  Susanne U Franssen; Caroline Durrant; Olivia Stark; Bettina Moser; Tim Downing; Hideo Imamura; Jean-Claude Dujardin; Mandy J Sanders; Isabel Mauricio; Michael A Miles; Lionel F Schnur; Charles L Jaffe; Abdelmajeed Nasereddin; Henk Schallig; Matthew Yeo; Tapan Bhattacharyya; Mohammad Z Alam; Matthew Berriman; Thierry Wirth; Gabriele Schönian; James A Cotton
Journal:  Elife       Date:  2020-03-25       Impact factor: 8.140

3.  Comparative transcriptomic analysis of antimony resistant and susceptible Leishmania infantum lines.

Authors:  Juvana Moreira Andrade; Leilane Oliveira Gonçalves; Daniel Barbosa Liarte; Davi Alvarenga Lima; Frederico Gonçalves Guimarães; Daniela de Melo Resende; Ana Maria Murta Santi; Luciana Marcia de Oliveira; João Paulo Linhares Velloso; Renato Guimarães Delfino; Pascale Pescher; Gerald F Späth; Jeronimo Conceição Ruiz; Silvane Maria Fonseca Murta
Journal:  Parasit Vectors       Date:  2020-11-30       Impact factor: 3.876

Review 4.  Global distribution of treatment resistance gene markers for leishmaniasis.

Authors:  Samira Salari; Mehdi Bamorovat; Iraj Sharifi; Pooya Ghasemi Nejad Almani
Journal:  J Clin Lab Anal       Date:  2022-07-09       Impact factor: 3.124

5.  Transcriptome Analysis of Intracellular Amastigotes of Clinical Leishmania infantum Lines from Therapeutic Failure Patients after Infection of Human Macrophages.

Authors:  Raquel García-Hernández; Ana Perea-Martínez; José Ignacio Manzano; Laura C Terrón-Camero; Eduardo Andrés-León; Francisco Gamarro
Journal:  Microorganisms       Date:  2022-06-27

6.  Application of CRISPR/Cas9-Based Reverse Genetics in Leishmania braziliensis: Conserved Roles for HSP100 and HSP23.

Authors:  Vanessa Adaui; Constanze Kröber-Boncardo; Christine Brinker; Henner Zirpel; Julie Sellau; Jorge Arévalo; Jean-Claude Dujardin; Joachim Clos
Journal:  Genes (Basel)       Date:  2020-09-30       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.